兴奋剂剂量与给药策略对注意缺陷多动障碍儿童青少年治疗结局的影响:一项Meta分析
该研究纳入65项随机对照试验共7877名儿童青少年,采用剂量-反应Meta分析分别评估哌甲酯和安非他明的疗效与耐受性。固定剂量试验中剂量增加可提高疗效但增加因不良事件停药风险,灵活剂量试验中剂量增加则同时改善疗效与可接受性。
要点
- 固定剂量试验中,哌甲酯超过30 mg或安非他明超过20 mg后疗效增量收益下降。
- 灵活剂量试验中,两种兴奋剂在FDA许可剂量范围内疗效增量收益保持恒定。
- 灵活滴定至更高剂量与疗效和可接受性改善相关,因可根据症状和不良事件调整剂量。
核心结论
- 灵活滴定至更高剂量与疗效和可接受性改善相关,因可根据ADHD症状控制和剂量限制性不良事件调整剂量。
- FDA要求的固定剂量试验虽有助于描述剂量依赖性,但可能低估临床实践中尝试增加兴奋剂剂量的真实潜在获益。
- 需要进一步研究调查临床实践中使用高剂量兴奋剂的潜在长期影响。
研究设计与样本
- 系统综述与剂量-反应Meta分析,纳入65项随机对照试验共7877名儿童青少年。
- 采用一阶段随机效应剂量-反应Meta分析,分别评估哌甲酯和安非他明,并按固定剂量与灵活剂量设计分层。
- 每日剂量通过校正不同制剂药代动力学转换为哌甲酯等效剂量和安非他明等效剂量。
- 进行配对Meta分析以间接比较灵活剂量与固定剂量试验。
主要发现
- 固定剂量试验中,哌甲酯和安非他明剂量增加均与疗效增加及因不良事件停药可能性增加相关。
- 固定剂量试验中,哌甲酯超过30 mg或安非他明超过20 mg后疗效增量收益下降。
- 灵活剂量试验中,哌甲酯和安非他明剂量增加均与疗效增加及因任何原因停药可能性降低相关。
- 灵活剂量试验中,哌甲酯和安非他明在FDA许可剂量范围内疗效增量收益保持恒定。
临床怎么用
- 临床指南目前推荐 practitioners 滴定兴奋剂药物(哌甲酯和安非他明)至症状控制最大化且不引起不可耐受不良事件的剂量。
- 作者认为,根据ADHD症状和剂量限制性不良事件灵活滴定至更高剂量与疗效和可接受性改善相关。
- 作者指出,固定剂量试验可能低估临床实践中尝试增加兴奋剂剂量的真实潜在获益。
局限性
- 需要进一步研究调查临床实践中使用高剂量兴奋剂的潜在长期影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clinical guidelines currently recommend practitioners titrate stimulant medications, i.e., methylphenidate (MPH) and amphetamines (AMP), to the dose that maximizes symptom control without eliciting intolerable adverse events (AEs) when treating attention-deficit/hyperactivity disorder (ADHD) in school-aged children/adolescents. However, robust evidence-base regarding the effects of doses and dosing strategies of stimulants on clinical outcomes in the treatment of children/adolescents with ADHD is currently lacking and stimulants are often underdosed in clinical practice. To address this gap and provide rigorous evidence-base in relation to the dose and dosing strategy of stimulants, we conducted the largest systematic review and dose-response meta-analysis examining change in ADHD symptoms (efficacy), and treatment discontinuations due to AEs (tolerability) and any reason (acceptability). We conducted one-stage random-effects dose-response meta-analyses examining MPH and AMP separately, stratifying trials based on fixed-dose and flexible-dose design. Daily doses of stimulants were converted to MPH- and AMP-equivalent doses by adjusting for different pharmacokinetics across formulations. We also conducted pairwise meta-analyses to provide indirect comparisons between flexible-dose versus fixed-dose trials. Our study included 65 RCTs involving 7 877 children/adolescents. Meta-analyses of fixed-dose trials for both MPH and AMP demonstrated increased efficacy and increased likelihood of discontinuation due to AEs with increasing doses of stimulants. The incremental benefits of stimulants in terms of efficacy decreased beyond 30 mg of MPH or 20 mg of AMP in fixed-dosed trials. In contrast, meta-analyses of flexible-dose trials for both MPH and AMP demonstrated increased efficacy and reduced likelihood of discontinuations for any reason with increasing stimulant doses. The incremental benefits of stimulants in terms of efficacy remained constant across the FDA-licensed dose range for MPH and AMP in flexible-dose trials. Our results suggest that flexible titration as needed, i.e., considering the presence of ADHD symptoms, and tolerated, i.e., considering the presence of dose-limiting AEs, to higher doses of stimulants is associated with both improved efficacy and acceptability because practitioners can increase/reduce doses based on control of ADHD symptoms/dose-limiting AEs. Although fixed-dose trials that are required by the FDA are valuable to characterize dose-dependency, they may underestimate the true potential benefit of trialing dose-increases of stimulants in clinical practice by not allowing dose adjustment based on response and tolerability. Additional research is required to investigate potential long-term effects of using high doses of stimulants in clinical practice.
引用
- Farhat LC, Flores JM, Behling E, et al. The effects of stimulant dose and dosing strategy on treatment outcomes in attention-deficit/hyperactivity disorder in children and adolescents: a meta-analysis. Mol Psychiatry. 2022. PMID: 35027679. doi:10.1038/s41380-021-01391-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。